Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies
Lucas Nogueira1, Andrew T Tracey1, Ricardo Alvim1
1Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Molecules (Basel, Switzerland)
|November 24, 2020
Summary
Photodynamic therapy (PDT) is gaining traction for focal cancer treatment in urologic oncology. Vascular-targeted PDT (VTP) with padeliporfin shows promise for precise tumor destruction and improved patient outcomes.
Area of Science:
- Urologic Oncology
- Photodynamic Therapy
- Cancer Biology
Background:
- Advancements in cancer biology and non-invasive treatments have renewed interest in photodynamic therapy (PDT) for urological malignancies.
- Development of improved photosensitizers has expanded PDT applications.
- Vascular-targeted PDT (VTP) utilizes specific agents for tumor-specific effects.
Purpose of the Study:
- To review the evolution of photodynamic therapy in urologic oncology.
- To highlight the role of vascular-targeted PDT (VTP) in current and future treatment strategies.
Main Methods:
- Review of historical and current literature on photodynamic therapy in urologic oncology.
- Focus on vascular-targeted PDT (VTP) using padeliporfin.
- Discussion of treatment paradigms and efficacy.
Main Results:
- Photodynamic therapy (PDT) offers a focal treatment option for urological cancers.
- Vascular-targeted PDT (VTP) with padeliporfin demonstrates efficacy through tumor-specific cytotoxicity.
- Padeliporfin is a well-tolerated, water-soluble chlorophyll derivative.
Conclusions:
- Photodynamic therapy (PDT) is an evolving treatment modality in urologic oncology.
- Vascular-targeted PDT (VTP) represents a significant advancement in focal cancer treatment.
- VTP holds potential for future urologic cancer management paradigms.
